PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 2nd, 2024 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • New York
This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agent”) shall be engaged by BriaCell Therapeutics Corp., a corporation formed under the laws of the Province of British Columbia (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of BriaCell Therapeutics Corp., the “Company”), to act as the exclusive placement agent in connection with the offering (hereinafter referred to as the “Offering”) of up to 5,128,500 units (the “Units”) of the Company, consisting of 5,128,500 Class A Units (as defined below) and 0 Class B Units (as defined below), each consisting of either: (A) one common share, with no par value per common share (each, a “Common Share”) and one warrant (each, a “Warrant”) to purchase one Common Share at an exercise price of $0.85 for a peri
Placement Agent’s Warrant Agreement WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP.BriaCell Therapeutics Corp. • October 2nd, 2024 • Pharmaceutical preparations
THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 2, 2024 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the Effective Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BriaCell Therapeutics Corp., a British Columbia corporation (the “Company”), up to ______ Common Shares, without par value per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
